|
1
|
Moore MA and Tajima K: Cervical cancer in
the asian pacific-epidemiology, screening and treatment. Asian Pac
J Cancer Prev. 5:349–361. 2004.PubMed/NCBI
|
|
2
|
Walboomers JM, Jacobs MV, Manos MM, et al:
Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chouaib S, Asselin-Paturel C, Mami-Chouaib
F, Caignard A and Blay JY: The host-tumor immune conflict: from
immunosuppression to resistance and destruction. Immunol Today.
18:493–497. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou JH, Ye F, Chen HZ, Zhou CY, Lu WG and
Xie X: Altered expression of cellular membrane molecules of HLA-DR,
HLA-G and CD99 in cervical intraepithelial neoplasias and invasive
squamous cell carcinoma. Life Sci. 78:2643–2649. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee
E, Pardoll D and Levitsky H: Role of bone marrow-derived cells in
presenting MHC class I-restricted tumor antigens. Science.
264:961–965. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ardavin C, Martinez del Hoyo G, Martin P,
et al: Origin and differentiation of dendritic cells. Trends
Immunol. 22:691–700. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fidler IJ and Kleinerman ES:
Lymphokine-activated human blood monocytes destroy tumor cells but
not normal cells under cocultivation conditions. J Clin Oncol.
2:937–943. 1984.
|
|
8
|
Kleinerman ES, Ceccorulli LM, Bonvini E,
Zicht R and Gallin JI: Lysis of tumor cells by human blood
monocytes by a mechanism independent of activation of the oxidative
burst. Cancer Res. 45:2058–2064. 1985.PubMed/NCBI
|
|
9
|
Ditschkowski M, Kreuzfelder E, Rebmann V,
et al: HLA-DR expression and soluble HLA-DR levels in septic
patients after trauma. Ann Surg. 229:246–254. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gabrilovich DI, Corak J, Ciernik IF,
Kavanaugh D and Carbone DP: Decreased antigen presentation by
dendritic cells in patients with breast cancer. Clin Cancer Res.
3:483–490. 1997.PubMed/NCBI
|
|
11
|
Pinzon-Charry A, Ho CS, Maxwell T, et al:
Numerical and functional defects of blood dendritic cells in early-
and late-stage breast cancer. Br J Cancer. 97:1251–1259. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Novellino PS, Trejo YG, Beviacqua M,
Bordenave RH and Rumi LS: Cisplatin containing chemotherapy
influences HLA-DR expression on monocytes from cancer patients. J
Exp Clin Cancer Res. 18:481–484. 1999.PubMed/NCBI
|
|
13
|
Novellino PS, Trejo YG, Beviacqua M,
Bordenave RH and Rumi LS: Regulation of HLA-DR antigen in monocytes
from colorectal cancer patients by in vitro treatment with human
recombinant interferon-gamma. J Investig Allergol Clin Immunol.
10:90–93. 2000.PubMed/NCBI
|
|
14
|
Woiciechowsky C, Asadullah K, Nestler D,
et al: Diminished monocytic HLA-DR expression and ex vivo cytokine
secretion capacity in patients with glioblastoma: effect of tumor
extirpation. J Neuroimmunol. 84:164–171. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Bokhorst-De van der Schuer MA, von
Blomberg-van der Flier BM, Riezebos RK, et al: Differences in
immune status between well-nourished and malnourished head and neck
cancer patients. Clin Nutr. 17:107–111. 1998.PubMed/NCBI
|
|
16
|
Gebhard B, Gnant M, Schutz G, et al:
Different transendothelial migration behaviour pattern of blood
monocytes derived from patients with benign and malignant diseases
of the breast. Anticancer Res. 20:4599–4604. 2000.PubMed/NCBI
|
|
17
|
Matsuoka T, Tabata H and Matsushita S:
Monocytes are differentially activated through HLA-DR, -DQ, and -DP
molecules via mitogen-activated protein kinases. J Immunol.
166:2202–2208. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Becker JC, Czerny C and Brocker EB:
Maintenance of clonal anergy by endogenously produced IL-10. Int
Immunol. 6:1605–1612. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wahl SM, McCartney-Francis N and
Mergenhagen SE: Inflammatory and immunomodulatory roles of
TGF-beta. Immunol Today. 10:258–261. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Le Bouteiller P: HLA class I chromosomal
region, genes, and products: facts and questions. Crit Rev Immunol.
14:89–129. 1994.PubMed/NCBI
|
|
21
|
Van Gool SW, Vandenberghe P, de Boer M and
Ceuppens JL: CD80, CD86 and CD40 provide accessory signals in a
multiple-step T-cell activation model. Immunol Rev. 153:47–83.
1996.PubMed/NCBI
|
|
22
|
Harding FA, McArthur JG, Gross JA, Raulet
DH and Allison JP: CD28-mediated signalling co-stimulates murine T
cells and prevents induction of anergy in T-cell clones. Nature.
356:607–609. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Girndt M, Sester M, Sester U, Kaul H and
Kohler H: Defective expression of B7-2 (CD86) on monocytes of
dialysis patients correlates to the uremia-associated immune
defect. Kidney Int. 59:1382–1389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu DM, Dustin ML, Cairo CW, Thatte HS and
Golan DE: Mechanisms of cellular avidity regulation in
CD2-CD58-mediated T cell adhesion. ACS Chem Biol. 1:649–658. 2006.
View Article : Google Scholar : PubMed/NCBI
|
